Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date

Mantle cell lymphoma (MCL) is an uncommon B-cell non-Hodgkin lymphoma characterized by an aggressive clinical course in the majority of patients. Despite recent improvements in outcomes, MCL remains incurable and a major therapeutic challenge. BTK inhibitors are the preferred treatment option for pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Sawalha, Yazeed, Bond, David A, Alinari, Lapo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351990/
https://www.ncbi.nlm.nih.gov/pubmed/32753893
http://dx.doi.org/10.2147/OTT.S238832

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351990/
https://www.ncbi.nlm.nih.gov/pubmed/32753893
http://dx.doi.org/10.2147/OTT.S238832

Ejemplares similares